ArticleInternational journal of cancer2026
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Existing prognostic scores for metastatic colorectal cancer (mCRC) are based on randomized clinical trial data and focus on parameters evaluated at the start of first-line (1L) treatment. Unlike these, the modified mCRC prognostic score (mCCS) was developed using real-world data from the German tumor registry colorectal cancer (TKK) and is based on pre-1L treatment information. It predicts overall survival (OS) for patients with RAS-wild-type (WT) mCRC using five tumor characteristics identified as independent negative prognostic factors. The mCCS aims to facilitate risk-based treatment approaches and optimize mCRC treatment. The VALIDATE study was a prospective, non-interventional study designed to validate the modified mCCS, recruiting patients with RAS-WT mCRC in Germany and Austria. A total of 646 patients from 113 study sites were enrolled in VALIDATE and received 1L therapy with panitumumab in combination with FOLFOX/FOLFIRI. Patients were categorized into risk groups according to the modified mCCS. The prognostic value of the modified mCCS was prospectively validated by demonstrating significantly longer median OS of patients in the low-risk group (29.1 months [25.9, 32.1]) compared to those in the high-risk group (20.1 months, [15.0, 23.9]). Rates of secondary resections of metastases were ≥ 23% for low and intermediate-risk patients, indicating a pivotal opportunity for improved prognosis. During panitumumab administration, patient-reported quality of life was preserved, and the tolerability profile was manageable with no new safety signals. The modified mCCS could serve as a practical tool for oncologists in routine clinical practice to aid in treatment decision-making and effectively communicating prognosis to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.